On January 8, the NMPA website showed that Hansoh Pharma’s aumolertinib mesylate tablets (Ameile) were approved for a new indication (acceptance number: CXHS2400127). In combination with pemetrexed and platinum chemotherapy, the drug is indicated for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations.
Aumolertinib was developed by Hansoh Pharma. Through the innovative introduction of a cyclopropyl structure, it has good lipophilicity and stability, can better penetrate the blood-brain barrier, and has a low incidence of adverse reactions. Aumolertinib was the first domestically developed third-generation EGFR-TKI to be approved in China, having first been approved in March 2020 and added to the national reimbursement drug list through negotiation later that year. This is the fifth approved indication for aumolertinib.
This approval was based on a Phase III registration trial known as AENEAS2. The randomized, open-label, multicenter Phase III study enrolled 624 patients with locally advanced (stage IIIB–IIIC) or metastatic (stage IV) EGFR-mutant NSCLC. Patients received once-daily oral aumolertinib 110 mg together with chemotherapy every three weeks for four cycles, consisting of pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 or carboplatin (AUC5), followed by maintenance therapy with aumolertinib plus pemetrexed every three weeks.
In October 2024, blinded independent central review showed that the AENEAS2 trial reduced the risk of disease progression or death by more than 50% with statistical significance in patients receiving aumolertinib plus chemotherapy. Median PFS exceeded two years. The safety results were consistent with the known safety profiles of the individual agents and no new safety signals were identified.
At the 2025 American Association for Cancer Research (AACR) Annual Meeting, Hansoh presented detailed data from the trial. As of June 18, 2024, 624 patients had been enrolled, including 310 in the aumolertinib-plus-chemotherapy group and 314 in the aumolertinib monotherapy group, stratified by EGFR mutation type (Ex19del vs. L858R) and baseline central nervous system metastasis status.
Median follow-up was 23.4 months. Median PFS was 28.9 months (95% CI 26.3–not available) in the combination group and 18.9 months (95% CI 17.8–21.1) in the monotherapy group, with a hazard ratio of 0.471 (95% CI 0.371–0.598; P<0.0001), and benefit was consistent across all prespecified subgroups. Overall survival data were not yet mature, with a hazard ratio of 0.442 (95% CI 0.308–0.636; P<0.0001).
In terms of safety, grade 3 or higher adverse events occurred in 75.7% of the combination group versus 23.7% of the monotherapy group; adverse events leading to discontinuation of aumolertinib occurred in 3.0% versus 1.3%, respectively. The median number of pemetrexed treatment cycles was 20.0, and 88.8% of patients completed 4–6 cycles of platinum chemotherapy. The safety profile of the combination was consistent with the known safety features of monotherapy.
Competition among EGFR inhibitors in China is particularly intense. According to the Insight database, eight third-generation EGFR-TKIs have already been approved in the country. Among domestic peers, aumolertinib has the broadest and fastest indication layout and remains in the leading tier.